蔚蓝生物(603739) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 reached ¥1,320,761,061.74, representing a 10.16% increase compared to ¥1,198,902,103.15 in 2023[25] - The net profit attributable to shareholders for 2024 was ¥62,637,482.98, a decrease of 22.39% from ¥80,706,911.48 in 2023[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,154,344.46, down 40.36% from ¥42,178,764.38 in 2023[25] - The net cash flow from operating activities increased by 27.22% to ¥195,407,571.77 in 2024, compared to ¥153,592,321.71 in 2023[25] - The total assets at the end of 2024 were ¥2,981,000,556.19, a decrease of 1.75% from ¥3,034,057,625.33 at the end of 2023[25] - The net assets attributable to shareholders increased by 1.72% to ¥1,737,720,580.05 at the end of 2024, compared to ¥1,708,293,232.64 at the end of 2023[25] - The basic earnings per share for 2024 were ¥0.25, down 21.88% from ¥0.32 in 2023[26] - The diluted earnings per share for 2024 were also ¥0.25, reflecting a 21.88% decrease from ¥0.32 in 2023[26] - The weighted average return on net assets for 2024 was 3.64%, a decrease of 1.18 percentage points from 4.82% in 2023[26] Revenue Breakdown - The enzyme preparation business generated revenue of CNY 50,474.96 million, with a year-on-year increase of CNY 6,330.11 million, representing a growth rate of 14.34%[32] - The company's main business income reached CNY 1,281,793,748.24, an increase of 8.86% year-on-year, while the main business cost rose by 11.53% to CNY 712,125,052.30[69] - The revenue from overseas markets was 99,948,895.67, showing a significant increase of 19.98% year-over-year[71] - Domestic sales accounted for 1,181,844,852.57, representing an 8.02% increase from the previous year[71] Research and Development - Research and development expenses amounted to CNY 11,822.23 million, accounting for 8.95% of operating revenue, with a year-on-year growth of 6.81%[32] - The company invested CNY 118.22 million in R&D, accounting for 8.95% of its revenue, which is considered high in the industry[58] - The company has established six technology centers and two key laboratories, employing 266 dedicated R&D personnel[56] - The company has developed a high-throughput screening technology platform for microbial strains, enhancing its ability to innovate and apply new products across various sectors[45] - The company is actively developing new animal vaccines and antibiotic enhancement platforms to improve clinical outcomes and reduce antibiotic resistance[61] Market Trends and Opportunities - The enzyme and micro-ecological agent industry is in a growth phase, benefiting from increasing national emphasis on safety and environmental protection[38] - The demand for enzyme preparations is expected to continue growing due to increasing environmental protection standards and policies promoting carbon neutrality[39] - The global probiotics market is rapidly growing, with applications expanding beyond gut health to include weight management and skin health, indicating a shift towards high-value product development in the food industry[41] - The agricultural sector faces significant challenges due to soil degradation and pesticide residues, creating opportunities for microbial preparations and bio-fertilizers to improve soil health and sustainability[41] Corporate Governance and Management - The total remuneration for the board members and senior management during the reporting period amounts to CNY 568.83 million[154] - The company has maintained strict confidentiality obligations during the preparation of regular reports and significant matters, with no leakage incidents reported[153] - The total number of shares held by all board members and senior management remains unchanged at 17,409,720 shares[154] - The company held six board meetings during the year, with all directors attending[160] Environmental Initiatives - The company invested 1,178,300 RMB in environmental protection during the reporting period[189] - The company’s enzyme products are estimated to have reduced carbon dioxide emissions by approximately 2.5919 million tons in downstream applications[191] - The application of microbial agents in agriculture can fundamentally reduce the use of chemical fertilizers and pesticides, thus minimizing soil and water pollution[194] Future Outlook - The company aims to leverage its R&D capabilities to ensure steady growth in performance through innovative product offerings and market expansion strategies[103] - The company is committed to building a fair organizational environment and enhancing employee satisfaction through various development programs and cultural activities[197] - The company plans to enhance its traditional Chinese medicine production processes and expand into upstream raw material businesses to reduce costs and improve quality[143]